
Kluwer Patent Blog

UK: Warner-Lambert Co LLC v. Actavis Group PTC, High Court of England and Wales, Chancery Division, Patents Court, HP-2014-000035 HP-2014-000021 HP-2014-001795, 10 September 2015

Thomas Hendicott (Bristows) · Wednesday, March 23rd, 2016

The U.K. Patents Court has held Warner-Lambert's second medical use patent regarding the use of pregabalin for the treatment of pain invalid on the ground of insufficiency. Even if the patent were valid, the Court held that Actavis would not have infringed Warner-Lambert's patent as a result of any "cross-label" use of their product sold on a skinny label.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Wednesday, March 23rd, 2016 at 10:29 am and is filed under [Case Law](#), [United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.